Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data

SpliceIO 的全面验证和商业准备,这是一个使用 RNA-seq 数据发现新抗原的软件平台

基本信息

  • 批准号:
    10838973
  • 负责人:
  • 金额:
    $ 7.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Accurate splicing is critical for the assembly of viable mRNA isoforms. Splicing errors, resulting in disease- causing mRNAs, occur frequently. In fact, ~50% of all cancer-driving synonymous mutations are predicted to cause splicing errors. Since the introduction of analytic software to quantify alternative splicing (AS) from RNA sequencing (RNAseq) data, evidence pointing to the importance of splicing regulation in cancer has mounted. Splicing errors are a major source of tumor-specific neoantigens, thus splicing research opens tremendous opportunities for the development of cancer immunotherapeutics and preventives. Envisagenics has developed SpliceIO, a software platform for neoantigen discovery using only RNAseq data. Most other methods for neoantigen prediction rely on whole-exome sequencing for the discovery of mutation-based neoantigens, a method that is not amenable to cancers with low tumor mutational burden (TMB), such as breast, prostate, pancreatic, pediatric tumors and other benign conditions. These cancers, however, are rich in splicing errors which can be detected with SpliceIO, making neoantigen discovery possible in this currently underserved area of medical need. Moreover, current methods predict neoantigens based on their ability to bind and be presented by MHC molecules which are downregulated in >60% of late-stage tumors. Since SpliceIO focuses on splicing errors it has the ability to predict both MHC-presented and MHC-independent antigens that are directly bound to the cell surface. The goal of this Direct-to-Phase II proposal is to build upon strong preliminary data and attain commercial readiness for SpliceIO. Envisagenics has been at the forefront of RNAseq-based target discovery since the development and commercialization of SpliceCore®, a software platform for the identification of druggable splicing isoforms. Envisagenics will utilize a proven commercialization strategy, which consists of comprehensive experimental validation to solidify a strong value proposition and commercial offering to prospective biopharma partners. In this proposal, we will develop a novel strategy for large-scale neoantigen validation using tandem mass spectrometry (MS/MS). In addition, we will scale identification of neoantigens using mammary organoids from BRCA1/2 mutation carriers. We present preliminary data equivalent to results from a Phase I SBIR and demonstrate the utility of splicing-derived target discovery for cancer therapeutics. To accomplish these goals and obtain commercial readiness for SpliceIO we will complete the following specific aims in this proposal: Aim 1: Develop a high-depth/high-sensitivity reference proteome for SpliceIO validation using MS/MS data. Aim 2: Neoantigen identification in BRCA1/2 mutation carriers using ultra-deep sequencing. Aim 3: Experimental validation of splicing-derived neoantigens. Completion of these aims will bring SpliceIO to a level of development proven to support successful commercialization and make a significant difference patient treatment and clinical care.
项目摘要 准确剪接对于活mRNA同种型的组装是至关重要的。拼接错误,导致疾病- 引起mRNA的基因突变。事实上,约50%的癌症驱动同义突变被预测为 导致拼接错误。自从引入分析软件来定量RNA的选择性剪接(AS)以来, 通过RNA测序(RNAseq)数据,已经有证据表明剪接调控在癌症中的重要性。 剪接错误是肿瘤特异性新抗原的主要来源,因此剪接研究打开了巨大的 癌症免疫治疗和预防药物的发展机会。Envisagenics开发了 SpliceIO,一种仅使用RNAseq数据进行新抗原发现的软件平台。大多数其他方法 新抗原预测依赖于全外显子组测序来发现基于突变的新抗原, 不适用于具有低肿瘤突变负荷(TMB)的癌症,如乳腺癌,前列腺癌, 胰腺、小儿肿瘤和其他良性疾病。然而,这些癌症富含剪接错误, 这可以用SpliceIO检测,使得在这个目前服务不足的领域发现新抗原成为可能 医疗需求。此外,目前的方法基于其结合和呈递的能力来预测新抗原。 MHC分子在> 60%的晚期肿瘤中下调。由于SpliceIO专注于拼接 它有能力预测直接结合的MHC呈递和MHC非依赖性抗原, 细胞表面。 该直接进入第二阶段提案的目标是建立在强大的初步数据基础上, 为SpliceIO做好准备。Envisagenics一直处于基于RNAseq的靶标发现的最前沿, 开发和商业化的SpliceCore®,一个软件平台,用于识别药物 剪接异构体Envisagenics将利用成熟的商业化战略,包括全面的 实验验证,以巩固强大的价值主张和商业产品,以未来的生物制药 伙伴在这项提案中,我们将开发一种新的策略,使用串联 质谱法(MS/MS)。此外,我们将使用乳腺类器官对新抗原进行规模鉴定, BRCA1/2突变携带者我们目前的初步数据相当于第一阶段SBIR的结果, 展示了剪接衍生的靶发现对于癌症治疗的效用。 为了实现这些目标并使SpliceIO具备商业化的条件,我们将完成以下工作 本提案的具体目标:目标1:为SpliceIO开发一个高深度/高灵敏度的参考蛋白质组 使用MS/MS数据进行验证。目的2:使用超深杂交技术鉴定BRCA 1/2突变携带者中的新抗原 测序目的3:剪接衍生的新抗原的实验验证。这些目标的实现将带来 SpliceIO的发展水平证明,支持成功的商业化,并作出重大的 区别患者治疗和临床护理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN AKERMAN其他文献

MARTIN AKERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN AKERMAN', 18)}}的其他基金

Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data
SpliceIO 的全面验证和商业准备,这是一个使用 RNA-seq 数据发现新抗原的软件平台
  • 批准号:
    10647773
  • 财政年份:
    2022
  • 资助金额:
    $ 7.7万
  • 项目类别:
Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data
SpliceIO 的全面验证和商业准备,这是一个使用 RNA-seq 数据发现新抗原的软件平台
  • 批准号:
    10482502
  • 财政年份:
    2022
  • 资助金额:
    $ 7.7万
  • 项目类别:
A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data
使用 RNA-seq 数据识别细胞表面抗原的软件平台
  • 批准号:
    9909639
  • 财政年份:
    2019
  • 资助金额:
    $ 7.7万
  • 项目类别:
SpliceCore: A cloud-based platform to detect, quantify and interpret alternative splicing variation from next-generation sequencing data.
SpliceCore:一个基于云的平台,用于检测、量化和解释下一代测序数据中的选择性剪接变异。
  • 批准号:
    8980250
  • 财政年份:
    2015
  • 资助金额:
    $ 7.7万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 7.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了